N/A
Completed N=1,229
Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
End Stage Renal Disease (ESRD)
Source: ClinicalTrials.gov NCT02604264 ↗
Enrolled (actual)
1,229
Serious AEs
0.0%
Results posted
May 2017
Primary outcomePrimary: Positive Blood Cultures (PBCs) Per 1,000 Central Venous Catheter (CVC)-Days — 0.26; 0.59 PBCs per 1,000 CVC-days
Summary
To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC) patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end caps.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Positive Blood Cultures (PBCs) Per 1,000 Central Venous Catheter (CVC)-Days |
0.26; 0.59 | — |
Eligibility Criteria
Inclusion Criteria
- All patients dialyzing with a central venous catheter
Exclusion Criteria
- Known allergy to chlorhexidine
Data sourced from ClinicalTrials.gov (NCT02604264). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.